MRTX - Bristol-Myers Squibb to acquire Mirati Therapeutics for $4.8B
2023-10-08 17:52:39 ET
More on Mirati Therapeutics
- Mirati: Expansion Of Adagrasib With sNDA And Combination Studies
- Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript
- As FDA mulls fate of Amgen drug, Sanofi could snap up rival Mirati
- FDA panel finds results from key Amgen Lumakras study unreliable
For further details see:
Bristol-Myers Squibb to acquire Mirati Therapeutics for $4.8B